ARCA was founded on the belief that a precision medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of patients, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. Gencaro™ (bucindolol hydrochloride) is an investigational compound with potential as a treatment for atrial fibrillation in patients with heart failure. ARCA has identified genetic variations in cardiac receptors that we believe may predict individual patient response to Gencaro™, giving Gencaro™ the potential to be the first genetically-targeted cardiovascular therapeutic.
Company Details
- Founded
- -
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://arcabio.com/
- Keywords
- biotechnology and cardiovascular.
Arca Biopharma Questions
Arca Biopharma's website is https://arcabio.com/
Arca Biopharma's LinkedIn profile is https://www.linkedin.com/company/arca-biopharma
Arca Biopharma's industry is
Biotechnology Research
Arca Biopharma's top competitors are
Edgewise Therapeutics,
Machavert Pharmaceuticals,
Bellerophon Therapeutics,
Aytu Biopharma,
Oruka Therapeutics,
Ampio Pharmaceuticals, Inc.,
Neurexis Therapeutics,
Statera Biopharma, Inc.,
Reven Pharmaceuticals,
Sintx Technologies.
Arca Biopharma's categories are Biotechnology Research
Arca Biopharma's founding year is 2007
